logo
Traces of Toxic Industrial Chemical Found in U.S. Air for the First Time

Traces of Toxic Industrial Chemical Found in U.S. Air for the First Time

Gizmodoa day ago

Americans' air is teeming with all sorts of known toxin pollutants—now scientists have found a new one to add to the list.
Researchers at the University of Colorado Boulder detailed their discovery in a study published earlier this month. They sampled agricultural sites in Oklahoma and found clear traces of medium-chain chlorinated paraffins (MCCPs) in the surrounding air. The health effects of MCCPs on people are still being studied, though countries are already planning to debate whether these chemicals should be regulated.
'It's very exciting as a scientist to find something unexpected like this that we weren't looking for,' said lead author Daniel Katz, a chemistry PhD student at CU Boulder, in a statement from the university. 'We're starting to learn more about this toxic, organic pollutant that we know is out there, and which we need to understand better.'
While environmental regulations in recent decades have greatly reduced levels of certain pollutants in the air and environment, such as lead, there are still many other lingering airborne toxins out there. Scientists have detected compounds like polychlorinated biphenyls (PCBs) phenylcyclohexene (PCH), and per- and polyfluoroalkyl substances (PFAS) in the air, for instance—many of which have the potential to disturb our hormones.
MCCPs and other chlorinated paraffins are common industrial chemicals. They're regularly used as flame retardants and plasticizers (substances that improve flexibility and softness) in a variety of applications. But research has started to suggest that much like short-chain chlorinated paraffins (SCCPs), MCCPs aren't without their risks. They appear to be toxic to marine and other aquatic environments, for instance. They might also persist in the environment and our bodies for a very long time, similar to so-called forever chemicals like per- and polyfluoroalkyl substances (PFAS).
The CU Boulder researchers weren't aiming to find MCCPs in the air—they were simply trying to document the general identity, distribution, and behavior of aerosol particles in the atmosphere. They planted a nitrate chemical ionization mass spectrometer at the study site for a month, 24 hours a day. To their surprise, they came across compounds with different patterns than expected, which they eventually determined were actually MCCPs.
Their findings, published in ACS Environmental Au, represent not only the first detection of airborne MCCPs in the U.S., but in the Western Hemisphere as a whole. MCCPs have been regularly found in wastewater, which can be recycled into biosolid fertilizer. So in this particular case, the researchers suspect that the chemicals came from the biosolid fertilizer used in the field near their study site.
'When sewage sludges are spread across the fields, those toxic compounds could be released into the air,' Katz said. 'We can't show directly that that's happening, but we think it's a reasonable way that they could be winding up in the air. Sewage sludge fertilizers have been shown to release similar compounds.'
SCCPs have been regulated in the U.S. and other countries for several years now. But experts argue that this regulation has spurred manufacturing industries to rely more on MCCPs as an alternative, leading to increased pollution. Members of the Stockholm Convention on Persistent Organic Pollutants, a UN-led international treaty that meets biannually to address potential threats to the environment and human health, are set to discuss this year whether MCCPs should be added to the list of organic chemicals that warrant regulation.
Whatever the verdict of the Stockholm Convention, the CU Boulder researchers say that much remains unknown about MCCPs. And they're hoping they and other scientists can continue to study these chemicals.
'We identified them, but we still don't know exactly what they do when they are in the atmosphere, and they need to be investigated further,' Katz said. 'I think it's important that we continue to have governmental agencies that are capable of evaluating the science and regulating these chemicals as necessary for public health and safety.'
Unfortunately, the U.S. Environmental Protection Agency may not be up to such a task currently. The renewed Trump administration has started to defang the EPA in all sorts of ways, from telling staffers to ease up on the fossil fuel industry to repealing already-created regulations on greenhouse emissions. MCCPs may be a real public health threat, but there's little indication that U.S. regulators will be interested in tackling them, at least under President Donald Trump.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

A Huge Update On ‘The Pitt' Season 2's Unusual Release Date On HBO Max
A Huge Update On ‘The Pitt' Season 2's Unusual Release Date On HBO Max

Forbes

time11 minutes ago

  • Forbes

A Huge Update On ‘The Pitt' Season 2's Unusual Release Date On HBO Max

The Pitt The Pitt is on course to land a bunch of Emmys, most likely, after its stellar run on Max (soon to be HBO Max). Now, WB wants to take advantage of this lightning in a bottle, and use it to create an entire thunderstorm on its service with rapid-fire, lengthy seasons like broadcast TV of old (I am told broadcast TV still exists). We have a big update about The Pitt season 2 from Max itself. They released a 'filming has begun' video on social media that confirms season 2 is not just written, it's already in motion. And yes, it's confirmed that The Pitt season 2's release date will be in January of 2026, one year after the January 9, 2025 release of the stunning 15-episode season 1. Stunning because the show was good, but also stunning because of the fact it was 15 episodes. And it's likely that season 2 will match that as it continues its 'single shift' concept, channeling 24 and Jack Bauer from years past. We know more than just the date, and here's a roundup of the information that we have about season 2: The Pitt More information will emerge in time, but it's crazy to think that with this announcement, we are already seven months away from a new season of the show. I cannot think of a single streaming show that produces 15, 45+ minute episodes once a year. Even ones that manage yearly releases are things like six-episode seasons of Slow Horses or shorter, fewer episodes like The Bear or Only Murders in the Building. The Pitt is something special, and hopefully, season 2 will retain season 1's quality. Follow me on Twitter, YouTube, Bluesky and Instagram. Pick up my sci-fi novels the Herokiller series and The Earthborn Trilogy.

A Drug for Hunger Offers Clues to Obesity's Complexity
A Drug for Hunger Offers Clues to Obesity's Complexity

Medscape

time11 minutes ago

  • Medscape

A Drug for Hunger Offers Clues to Obesity's Complexity

Ali Foley Shenk still remembers the panic when her 10-year-old son, Dean, finished a 20-ounce box of raisins in the seconds the cupboard was left unlocked. They rushed to the emergency room, fearing a dangerous bowel impaction. The irony stung: When Dean was born, he was so weak and floppy he survived only with feeding tubes because he couldn't suck or swallow. He was diagnosed as a baby with Prader-Willi syndrome — a rare disorder sparked by a genetic abnormality. He continued to be disinterested in food for years. But doctors warned that as Dean grew, his hunger would eventually become so uncontrollable he could gain dangerous amounts of weight and even eat until his stomach ruptured. 'It's crazy,' said Foley Shenk, who lives in Richmond, Virginia. 'All of a sudden, they flip.' Prader-Willi syndrome affects up to 20,000 people in the US. The most striking symptom is its most life-threatening: An insatiable hunger known as hyperphagia that prompts caregivers to padlock cupboards and fridges, chain garbage cans, and install cameras. Until recently, the only treatment was growth hormone therapy to help patients stay leaner and grow taller, but it didn't address appetite. In March, the Food and Drug Administration approved Vykat XR, an extended-release version of the existing drug diazoxide choline, which eases the relentless hunger and may offer insights into the biology of extreme appetite and binge eating. This breakthrough for these patients comes as other drugs are revolutionizing how doctors treat obesity, which affects more than 40% of American adults. GLP-1 agonist medications Ozempic, Wegovy, and others also are delivering dramatic results for millions. But what's becoming clear is that obesity isn't one disease — it's many, said Jack Yanovski, a senior obesity researcher at the National Institutes of Health, who co-authored some of the Vykat XR studies. Researchers are learning that obesity's drivers can be environmental, familial, or genetic. 'It only makes sense that it's complex to treat,' Yanovski said. Obesity medicine is likely heading the way of treatments for high blood pressure or diabetes, with three to five effective options for different types of patients. For example, up to 15% of patients in the GLP-1 trials didn't respond to those drugs, and at least one study found the medications didn't significantly help Prader-Willi patients. Yet, researchers say, efforts to understand how to treat obesity's many causes and pathways are now in question as the Trump administration is dismantling the nation's infrastructure for medical discovery. While Health and Human Services Secretary Robert F. Kennedy, Jr, promotes a 'Make America Healthy Again' agenda centered on diet and lifestyle, federal funding for health research is being slashed, including some grants that support the study of obesity. University labs face cuts, FDA staffers are being laid off en masse, and rare disease researchers fear the ripple effects across all medical advances. Even with biotech partnerships — such as the work that led to Vykat XR — progress depends on NIH-funded labs and university researchers. 'That whole thing is likely to get disrupted now,' said Theresa Strong, research director for the Foundation for Prader-Willi Research. HHS spokesperson Andrew Nixon said in a statement that no NIH awards for Prader-Willi syndrome research have been cut. 'We remain committed to supporting critical research into rare diseases and genetic conditions,' he said. But Strong said that already some of the contacts at the FDA she'd spent nearly 15 years educating about the disorder have left the agency. She's heard that some research groups are considering moving their labs to Europe. Early progress in hunger and obesity research is transforming the life of Dean Shenk. During the trial for Vykat XR, his anxiety about food eased so much that his parents began leaving cupboards unlocked. Jennifer Miller, a pediatric endocrinologist at the University of Florida who co-led the Vykat XR trials, treats around 600 Prader-Willi patients, including Dean. She said the impact she's seen is life-changing. Since the drug trial started in 2018, some of her adult patients have begun living independently, getting into college, and starting jobs — milestones that once felt impossible. 'It opens up their world in so many ways.' Over 26 years in practice, she's also seen just how severely the disease hurts patients. One patient ate a 4-lb bag of dehydrated potato flakes; another ingested all 10 frozen pizzas from a Costco pack; some ate pet food. Others have climbed out of windows, dived into dumpsters, even died after being hit by a car while running away from home in search of food. Low muscle tone, developmental delays, cognitive disabilities, and behavioral challenges are also common features of the disorder. Dean attends a special education program, his mother said. He also has narcolepsy and cataplexy — a sudden loss of muscle control triggered by strong emotions. His once-regular meltdowns and skin-picking, which led to deep, infected lesions, were tied to anxiety over his obsessive, almost painful urge to eat. In the trial, though, his hyperphagia was under control, according to Miller and Dean's mother. His lean muscle mass quadrupled, his body fat went down, and his bone mineral density increased. Even the skin-picking stopped, Foley Shenk said. Vykat XR is not a cure for the disease. Instead, it calms overactive neurons in the hypothalamus that release neuropeptide Y — one of the body's strongest hunger signals. 'In most people, if you stop secreting NPY, hunger goes away,' said Anish Bhatnagar, CEO of Soleno Therapeutics, which makes the medication, the company's first drug. 'In Prader-Willi, that off switch doesn't exist. It's literally your brain telling you, 'You're starving,' as you eat.' GLP-1 drugs, by contrast, mimic a gut hormone that helps people feel full by slowing digestion and signaling satiety to the brain. Vykat XR's possible side effects include high blood sugar, increased hair growth, and fluid retention or swelling, but those are trade-offs that many patients are willing to make to get some relief from the most devastating symptom of the condition. Still, the drug's average price of $466,200 a year is staggering even for rare-disease treatments. Soleno said in a statement it expects broad coverage from both private and public insurers and that the copayments will be 'minimal.' Until more insurers start reimbursing the cost, the company is providing the drug free of charge to trial participants. Soleno's stock soared 40% after the FDA nod and has held fairly steady since, with the company valued at nearly $4 billion as of early June. While Vykat XR may be limited in whom it can help with appetite control, obesity researchers are hoping the research behind it may help them decode the complexity of hunger and identify other treatment options. 'Understanding how more targeted therapies work in rare genetic obesity helps us better understand the brain pathways behind appetite,' said Jesse Richards, an internal medicine physician and the director of obesity medicine at the University of Oklahoma-Tulsa's School of Community Medicine. That future may already be taking shape. For Prader-Willi, two other notable phase 3 clinical trials are underway, led by Acadia Pharmaceuticals and Aardvark Therapeutics, each targeting different pathways. Meanwhile, hundreds of trials for general obesity are currently recruiting despite the uncertainties in US medical research funding. That brings more hope to patients like Dean. Nearly 6 years after starting treatment, the now-16-year-old is a calmer, happier kid, his mom said. He's more social, has friends, and can focus better in school. With the impulse to overeat no longer dominating his every thought, he has space for other interests — Star Wars, American Ninja Warrior, and a healthy appreciation for avocados among them. 'Before the drug, it just felt like a dead end. My child was miserable,' Foley Shenk said. 'Now, we have our son back.'

This Florida Beach Has the Highest Bacteria Rates in the State
This Florida Beach Has the Highest Bacteria Rates in the State

Travel + Leisure

time17 minutes ago

  • Travel + Leisure

This Florida Beach Has the Highest Bacteria Rates in the State

Not every beach or waterway in Florida is a pristine stretch of white beach. One stretch of water in Miami is officially dirty. The SurfRider foundation released their rankings of the top "Beach Bacteria Hot Spots" in the U.S., and it has declared Park View Kayak Launch in Miami Beach, Florida, as a bacteria hot spot, ranked at 90 percent. The water is highly polluted, making it unsafe for swimming. The Beach Bacteria Hot Spots that are ranked represent a variety of recreational waters, beaches, and access points that are important to local communities, but threaten public health. During 2024, SurfRider's Blue Water Task Force processed more than 10 thousand water samples from 604 sampling sites to determine which spots had unsafe levels of bacteria. The organization works to inform communities about public health, as well as advocate for the protection and clean-up of heavily polluted beaches. The Blue Water Task Force works year-round to provide public health protection even during the off-season when water samples generally are not being collected. The problem at Park View Kayak Launch began when a sewer main broke in March 2020, flooding the water with pollution. Usually, pollution from a sewer main break only lasts for a few days, but for many reasons, including outdated infrastructure, the pollution has persisted at Park View Kaway Launch for years. The city has an action plan to address the issue, but despite efforts, the water continues to have unsafe levels of sewage in it. 'The Park View Canal "no contact with the water" advisory remains in place for the area adjacent to the kayak launch at 73 Street. Water sampling results continue to show a fecal indicator bacteria concentration that exceeds recreational water quality standards established by the Florida Department of Health,' the Miami Beach website states. A "No Contact With Water" sign at the Kayak Launch. Visitors to Miami should be aware of the 'no contact' order and avoid getting too close to the sewage-polluted water, as it could be deleterious for health until the waterway is sufficiently cleaned. 'At Surfrider, we believe everyone should have access to clean water to surf, swim, and play in. Improving coastal water quality has been one of our top priorities since the Surfrider Foundation was founded in 1984,' the SurfRider website states.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store